Global Gene, Cell, and RNA Therapy Trends – Q3 2024 Update

The Q3 2024 report from the American Society of Gene and Cell Therapy (ASGCT) and Citeline highlights key developments in advanced molecular therapies. One major FDA approval this quarter was Tecelra, a synovial sarcoma therapy, underscoring the field’s continued expansion into non-oncology indications, which now represent 51% of new gene therapy trials. This trend marks a significant diversification from the traditional focus on oncology.

Globally, the therapy pipeline includes over 4,000 treatments, with nearly half being gene therapies. Among these, CAR-T therapies remain dominant, primarily targeting oncology. Dealmaking activity saw stability, with 101 transactions, while start-up financing rebounded dramatically, tripling from the previous quarter to $484 million.

For genomics and healthcare professionals in Australia, these insights reflect emerging global trends that may shape local research, regulation, and industry collaboration. Understanding these shifts can help align Australia’s efforts with the evolving international landscape.

Read the full report here, and follow InGeNA for ongoing updates on genomics advancements worldwide.